LGALS3 and metabolic dysfunction-associated steatohepatitis: Gal-3 has been found to attenuate steatosis while promoting liver injury, inflammation and fibrosis in an obesogenic mouse model of non-alcoholic steatohepatitis (NASH) (91–93).